These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model. Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S. Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914 [Abstract] [Full Text] [Related]
6. Protein vaccination with HPV16 E7/Pep-1 nanoparticles elicits a protective T-helper cell-mediated immune response. Mardani G, Bolhassani A, Agi E, Shahbazi S, Mehdi Sadat S. IUBMB Life; 2016 Jun; 68(6):459-67. PubMed ID: 27094221 [Abstract] [Full Text] [Related]
7. A Genetically Modified attenuated Listeria Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner. Jia YY, Tan WJ, Duan FF, Pan ZM, Chen X, Yin YL, Jiao XA. Front Cell Infect Microbiol; 2017 Jun; 7():279. PubMed ID: 28706878 [Abstract] [Full Text] [Related]
10. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth. Esquerré M, Momot M, Goubier A, Gonindard C, Leung-Theung-Long S, Misseri Y, Bissery MC. Vaccine; 2017 Mar 13; 35(11):1509-1516. PubMed ID: 28196735 [Abstract] [Full Text] [Related]
11. A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection. Demurtas OC, Massa S, Ferrante P, Venuti A, Franconi R, Giuliano G. PLoS One; 2013 Mar 13; 8(4):e61473. PubMed ID: 23626690 [Abstract] [Full Text] [Related]
12. Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate. Granadillo M, Batte A, Alfonso AB, Blanco A, Urquiza D, Varas L, Soler D, Miyares M, Limonta M, Torrens I. Vaccine; 2019 Jul 09; 37(30):3957-3960. PubMed ID: 31155419 [Abstract] [Full Text] [Related]
13. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells. Baghban Rahimi S, Mohebbi A, Vakilzadeh G, Biglari P, Razeghi Jahromi S, Mohebi SR, Shirian S, Gorji A, Ghaemi A. Arch Virol; 2018 Mar 09; 163(3):587-597. PubMed ID: 29149434 [Abstract] [Full Text] [Related]
14. In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses. Kayyal M, Bolhassani A, Noormohammadi Z, Sadeghizadeh M. Mol Biotechnol; 2021 Dec 09; 63(12):1192-1222. PubMed ID: 34308516 [Abstract] [Full Text] [Related]
16. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Bolhassani A, Zahedifard F, Taghikhani M, Rafati S. Vaccine; 2008 Jun 19; 26(26):3362-70. PubMed ID: 18471945 [Abstract] [Full Text] [Related]
17. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model. Daemi A, Bolhassani A, Rafati S, Zahedifard F, Hosseinzadeh S, Doustdari F. Immunol Lett; 2012 Dec 17; 148(2):117-25. PubMed ID: 23085605 [Abstract] [Full Text] [Related]
18. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model. Jia Y, Yin Y, Duan F, Fu H, Hu M, Gao Y, Pan Z, Jiao X. Int J Mol Med; 2012 Dec 17; 30(6):1335-42. PubMed ID: 23027427 [Abstract] [Full Text] [Related]